CN111713666A - Fat reducing composition and preparation method thereof - Google Patents
Fat reducing composition and preparation method thereof Download PDFInfo
- Publication number
- CN111713666A CN111713666A CN202010807727.6A CN202010807727A CN111713666A CN 111713666 A CN111713666 A CN 111713666A CN 202010807727 A CN202010807727 A CN 202010807727A CN 111713666 A CN111713666 A CN 111713666A
- Authority
- CN
- China
- Prior art keywords
- parts
- fat
- powder
- weight
- reducing composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 230000001603 reducing effect Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000000843 powder Substances 0.000 claims abstract description 81
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 30
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 27
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 27
- 239000003094 microcapsule Substances 0.000 claims abstract description 25
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 23
- 241000219122 Cucurbita Species 0.000 claims abstract description 21
- 235000009852 Cucurbita pepo Nutrition 0.000 claims abstract description 21
- 241000702462 Akkermansia muciniphila Species 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000009526 Fructus Akebiae Substances 0.000 claims abstract description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 210000004907 gland Anatomy 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 241000702460 Akkermansia Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 16
- 241000894006 Bacteria Species 0.000 abstract description 14
- 240000005662 Aronia melanocarpa Species 0.000 abstract description 12
- 235000007425 Aronia melanocarpa Nutrition 0.000 abstract description 12
- 238000001727 in vivo Methods 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 238000009825 accumulation Methods 0.000 abstract description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 abstract description 3
- 235000013824 polyphenols Nutrition 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 26
- 208000008589 Obesity Diseases 0.000 description 16
- 235000020824 obesity Nutrition 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 230000037406 food intake Effects 0.000 description 7
- 235000012631 food intake Nutrition 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000192125 Firmicutes Species 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 241000605059 Bacteroidetes Species 0.000 description 3
- 241000425347 Phyla <beetle> Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 210000005027 intestinal barrier Anatomy 0.000 description 3
- 230000007358 intestinal barrier function Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000013116 obese mouse model Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical group C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003870 intestinal permeability Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000219138 Luffa Species 0.000 description 1
- 235000003956 Luffa Nutrition 0.000 description 1
- 244000302544 Luffa aegyptiaca Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- WLJUMPWVUPNXMF-UHFFFAOYSA-L calcium;3-hydroxy-3-methylbutanoate Chemical group [Ca+2].CC(C)(O)CC([O-])=O.CC(C)(O)CC([O-])=O WLJUMPWVUPNXMF-UHFFFAOYSA-L 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010699 lard oil Substances 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 235000021278 navy bean Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a fat-reducing composition, which comprises the following raw materials in parts by weight: 30-40 parts of juice powder of the fructus akebiae, 10-20 parts of medium-chain triglyceride microcapsule powder, 10-20 parts of towel gourd powder, 3-13 parts of mucinous-Akkermansia (Akkermansia muciniphila) and 10-20 parts of fructo-oligosaccharide; the medium-chain triglyceride microcapsule powder and the aronia melanocarpa juice powder in the fat reducing composition are compounded to combust fat, inhibit fat synthesis, reduce fat accumulation in vivo and synergistically achieve the fat reducing effect; akk the bacteria and the towel gourd powder cooperate to regulate intestinal flora and realize the effect of controlling weight; the polyphenol and fructo-oligosaccharide in the Aronia melanocarpa juice powder synergistically improve the abundance of Akk bacteria, so that the fat reducing effect is achieved. The effects of 5 components are integrated, the compatibility is reasonable, the safety and the effectiveness are realized, and various components perform synergistic action through different ways, so that the fat burning is accelerated, the intestinal flora is adjusted, and the fat reduction is more efficient.
Description
Technical Field
The invention relates to a fat-reducing composition and a preparation method thereof, belonging to the field of functional foods.
Background
With the development of social civilization, the living standard of people is improved, and the incidence rate of simple obesity is increased year by year. According to the International Association for the Study of Obesity, IASO, it was shown that about 10 million people are overweight worldwide by 2010 (BMI 25-29.9 Kgm)2) More than 4.75 hundred million people are obese (BMI is more than or equal to 30 Kg/m)2)。
Although obesity occurs in association with a variety of factors such as genetic factors, social and environmental factors, psychological factors, etc., obesity occurs directly because more energy is consumed than consumed and the excess energy is stored in the form of fat, thereby causing obesity. Intestinal flora plays an important role in the processes of energy intake, transformation and storage, wherein the flora with absolute dominance in quantity only comprise Firmicutes and Bacteroidetes, and the other flora usually occupies a small proportion. The intestinal flora has specific metabolic efficiency: the host is decomposed into nutrients and provides an energy substrate. In recent years, researches show that the intestinal flora has certain correlation with the onset of obesity, and the mechanism of the intestinal flora relates to a plurality of aspects such as promotion of energy absorption, influence on intestinal mucosa permeability and secretion of appetite regulating factors, induction of endotoxemia, chronic inflammatory response states and the like.
Obesity not only affects the body, causes the imbalance of intestinal flora in the body, but also brings various complications such as diabetes, hypertension, cerebrovascular accident and the like, and harms the health of human beings. With the continuous and deep understanding of obesity hazards, more and more people participate in fat-reducing teams. Diet therapy, exercise therapy, behavior therapy, drug therapy and surgical diet therapy are commonly used as the basic method of obesity therapy. Based on this, a lot of weight-reducing products are produced.
At present, the number of weight-reducing products on the market is large, and 392 health-care foods with the weight-reducing function are found in the data network of the medicine intelligence until 2020.04 months, and a large amount of sports nutritional foods and functional foods which cannot be found are also found. However, the quality of a plurality of weight-losing products is also uneven, some products are expensive, and the weight-losing effect is not realized; some have good weight-losing effect but have obvious side effect; and some people are added with illegal chemical components, so that the body and mind of the people who lose weight are damaged.
CN110800904A discloses a solid beverage composition for effectively controlling body weight and reducing fat, which comprises inulin, fructo-oligosaccharide, whey protein powder, pea protein, navy bean extract, beta-hydroxy-beta-methylbutyrate calcium, l-carnitine, medium chain triglyceride, fruit and vegetable powder or tea powder, and sugar substitute. The effect of improving the intestinal lipid-reducing flora by adding fructo-oligosaccharide and inulin is not obvious.
Disclosure of Invention
Aiming at the defects of the prior art, especially the defects of poor fat reducing effect and obvious side effect of the current fat reducing products, the invention aims to provide a fat reducing composition and a preparation method of the fat reducing composition.
The fat-reducing composition can accelerate fat combustion, inhibit fat synthesis, regulate intestinal flora, synergistically achieve the effect of controlling weight, and is safe and free of side effect.
In order to solve the technical problems, the invention is realized by the following technical scheme:
a fat-reducing composition comprises the following raw materials in parts by weight: 30-40 parts of black fruit and rib flower fructus fagopyri juice powder, 10-20 parts of medium-chain triglyceride microcapsule powder, 10-20 parts of towel gourd powder, 3-13 parts of mucinous-akkermansia (Akkermansia muciniphila) and 10-20 parts of fructo-oligosaccharide.
According to the invention, preferably: the fat-reducing composition comprises the following raw materials in parts by weight: 33-37 parts of juice powder of fructus akebiae, 13-17 parts of medium-chain triglyceride microcapsule powder, 12-18 parts of towel gourd powder, 5-12 parts of mucinous-Akkermansia (Akkermansia muciniphila) and 12-17 parts of fructo-oligosaccharide.
According to the invention, preferably: the fat-reducing composition comprises the following raw materials in parts by weight: 36 parts of black fruit gland and rib flower fructus fagopyri powder, 15 parts of medium chain triglyceride microcapsule powder, 15 parts of towel gourd powder, 10 parts of mucinous-akkermansia (Akkermansia muciniphila) and 16 parts of fructo-oligosaccharide.
According to the invention, the preferable weight content of the medium chain triglyceride in the medium chain triglyceride microcapsule powder is 70-80%.
The preparation method of the fat-reducing composition comprises the following steps:
(1) sieving fructus Sorbi Pohuashanensis juice powder, medium chain triglyceride microcapsule powder, fructus Luffae powder, and fructo-oligosaccharide with 80 mesh sieve, mixing at a certain proportion to obtain mixture, and adding alcohol into the mixture to obtain soft material; then, granulating through a 20-mesh sieve, drying for 2-3 h at 50-60 ℃ after granulation, and then carrying out granulation and powder sieving to obtain a primary mixture;
(2) and (2) adding the mucinous-Ackermanella (Akkermansia muciniphila) into the primary mixture obtained in the step (1) according to the proportion, and mixing for 20-25 min to obtain the fat-reducing composition.
Preferably, in step (1), the alcohol concentration is 40% to 60% and the amount of alcohol added is 5% to 10% by weight of the mixture.
An oral preparation for reducing fat is prepared by adopting the fat-reducing composition, and the dosage form of the oral preparation is tablets, capsules or granules.
The invention has the technical characteristics that:
research shows that obesity is related to increase of systemic oxidative stress, increase of systemic inflammation and the like, and the aronia melanocarpa fruit contains rich nutrient components and bioactive substances: the biological active substances have antioxidant activity, can interfere the process related to oxidative stress, and protect in vitro neutrophils from oxidative damage of obese and non-obese individuals, thereby achieving the effect of losing weight; the nutrition and metabolism center of the medical research institute of Belglad university of Severum takes an abdominal obese person as a research object, and takes a supplement prepared from the aronia melanocarpa juice, and the result shows that the BMI and abdominal circumference of the experimental object are remarkably reduced, and the aronia melanocarpa fruit has the effect of controlling the weight. In addition, the aronia melanocarpa fruit has the highest oxidation resistance in fruits and can protect human cells from oxidation of substances such as free radicals and the like.
The medium-chain triglyceride (MCT) adopted by the invention is the triglyceride composed of fatty acid with 6-12 (also 8-10 or 8-12) carbon atoms. MCT has low energy density, small dependence on bile salt and pancreatin, and easy hydrolysis in intestinal tract, wherein medium-chain fatty acid in hydrolysate is absorbed and combined with albumin, and is directly transported to liver through portal vein; MCT directly enters the mitochondria of the liver cells to be oxidized without depending on carnitine, and the oxidation is rapid and complete, so the MCT is not easy to accumulate in adipose tissues and liver tissues; MCT increases energy expenditure, increases satiety to suppress appetite, thereby reducing weight gain and the volume of fat depots, and helps to reduce visceral fat and subcutaneous fat.
The towel gourd adopted by the invention improves lipid metabolism disorder caused by High Fat Diet (HFD) by inhibiting a signal path of lipid transportation and synthesis of liver, can also improve High Fat Diet (HFD) -induced intestinal flora imbalance of rats, increases the content of short-chain fatty acid and the abundance of related flora, keeps the integrity of intestinal barriers, and relieves the development of obesity, namely the towel gourd improves obesity by regulating the intestinal flora, particularly the enrichment of short-chain fatty acid producing bacteria.
The invention adopts muciniphilic-Ackermanella, which is Akk bacteria for short, and Latin is Akkermansia muciniphila (A. muciniphila), which is an oval gram-negative bacteria, is a resident of human intestinal tracts and accounts for 3-5% of human microbial community. It can grow in the mucus layer of the intestine and "feed" on mucins secreted by the host, thereby colonizing the intestine and protecting it from pathogens by competitive exclusion. Although the Akk bacterium has mucin as an energy source, a number of observations have demonstrated that Akk has a positive regulatory effect on intestinal mucus layer thickness and intestinal barrier integrity. The research shows that: the Akk bacteria level was lower in obese people than in healthy people, and Akk bacteria abundance also had a positive relationship with insulin sensitivity and healthier metabolic state. The abundance of Akk bacteria can be increased by feeding obese mice with polyphenols. Additional studies have shown that: oral administration of live Akk (mouse) can prevent obesity caused by diet by altering adipose tissue metabolism and intestinal permeability, without affecting appetite and dietary habits.
The fructo-oligosaccharide adopted by the invention is not easy to be absorbed by human bodies, can also obviously improve the microbial population ratio in intestinal tracts, is an activated proliferation factor of bifidobacterium in the intestinal tracts, can reduce and inhibit the generation of putrefactive substances in the intestinal tracts, inhibits the growth of harmful bacteria, regulates the balance in the intestinal tracts, and researches show that the Akk bacteria abundance is recovered after the fructo-oligosaccharide is fed to mice.
The invention can bring the following beneficial effects:
1. the bioactive substances of the aronia melanocarpa juice powder in the fat-reducing composition protect in-vitro neutrophils from oxidative damage of obese and non-obese individuals, inhibit fat synthesis and achieve the effect of losing weight; in addition, the Aronia melanocarpa juice powder can reduce the weight of white adipose tissues and the level of leptin, namely, the fat reducing effect is achieved by inhibiting fat synthesis and reducing the level of leptin. The medium chain triglyceride microcapsule powder provides less energy per gram (8.3kcal/9kcal), is not easy to store in fat tissue, helps the body to rapidly enter a fat burning mode, enhances thermogenesis, increases metabolic rate, accelerates fat burning, can increase energy consumption, and achieves the purpose of controlling weight. The luffa powder maintains the integrity of the intestinal barrier and reduces the development of obesity by increasing the content of short chain fatty acids and the abundance of related flora. Akk the strain can regulate intestinal flora by changing adipose tissue metabolism and intestinal permeability, and has effect in reducing fat.
2. The medium-chain triglyceride microcapsule powder and the aronia melanocarpa juice powder in the fat reducing composition are compounded to combust fat, inhibit fat synthesis, reduce fat accumulation in vivo and synergistically achieve the fat reducing effect; akk the bacteria and the towel gourd powder cooperate to regulate intestinal flora and realize the effect of controlling weight; the polyphenol and fructo-oligosaccharide in the Aronia melanocarpa juice powder synergistically improve the abundance of Akk bacteria, so that the fat reducing effect is achieved.
3. The fat-reducing composition integrates the effects of 5 components, is reasonable in compatibility, safe and effective, and has the advantages that various components perform synergistic action through different ways, the fat burning is accelerated, the intestinal flora is adjusted, and the fat reduction is more efficient.
Drawings
FIG. 1 is an analysis chart of relative abundance of main phyla in Experimental example 3.
Detailed Description
The present invention is described in detail with reference to specific examples, which are provided to facilitate the understanding of the technical solutions of the present invention by those skilled in the art, and the implementation or use of the present invention is not limited by the description of the present invention.
The mucinous-Ackermanella (Akkermansia muciniphila) used in the examples was obtained by a method of low-oxygen culture of mucinous-Ackermanella in accordance with CN110551658A, a Chinese patent document.
The Aronia melanocarpa juice powder is concentrated juice powder obtained by processing fresh Aronia melanocarpa fruits in the prior art, and 1kg of dry powder is obtained for every 10-30 kg of fresh fruits; available from Guangzhou Kangle food additives Co., Ltd; medium chain triglyceride microcapsule powder available from sienna guangyuan biotechnology limited; luffa cylindrica extract, available from Biotech limited of Nanjing Zealand; fructo-oligosaccharide is available from bowling Biotin GmbH.
Example 1
A fat-reducing composition comprises the following raw materials in parts by weight: 36 parts of black fruit gland and rib flower fructus fagopyri powder, 15 parts of medium chain triglyceride microcapsule powder, 15 parts of towel gourd powder, 10 parts of mucinous-Akkermansia (Akkermansia muciniphila) and 16 parts of fructo-oligosaccharide.
Example 2
A fat-reducing composition comprises the following raw materials in parts by weight: 40 parts of juice powder of the black fruit gland and rib flower, 20 parts of medium-chain triglyceride microcapsule powder, 10 parts of towel gourd, 13 parts of mucinous-Akkermansia (Akkermansia muciniphila) and 10 parts of fructo-oligosaccharide.
Example 3
A fat-reducing composition comprises the following components in parts by weight: 20 parts of immature bitter orange powder, 30 parts of black fruit gland and rib flower fructus Sorbi Pohuashanensis juice powder, 10 parts of medium-chain triglyceride microcapsule powder, 20 parts of towel gourd, 3 parts of mucinous-Akkermansia (Akkermansia), and 20 parts of fructo-oligosaccharide.
Example 4
A method of preparing a fat reducing composition comprising the steps of:
(1) sieving the raw materials of the juice powder of the black fruit and rib flower bud, the medium-chain triglyceride microcapsule powder, the towel gourd powder and the fructo-oligosaccharide with a 80-mesh sieve, uniformly mixing the raw materials in proportion to obtain a mixture, and adding alcohol accounting for 5-10 percent of the weight of the mixture into the mixture to obtain a soft material; then, granulating through a 20-mesh sieve, drying for 2-3 h at 50-60 ℃ after granulation, and then carrying out granulation and powder sieving to obtain a primary mixture;
(2) and (2) adding the mucinous-Ackermanella (Akkermansia muciniphila) into the primary mixture obtained in the step (1) according to the proportion, and mixing for 20-25 min to obtain the fat-reducing composition.
The fat-reducing composition can be prepared into various common oral dosage forms, including granules, tablets, capsules and the like.
Comparative example 1
A fat-reducing composition comprises the following components in parts by weight: 45 parts of black fruit and rib flower fructus fagopyri juice powder, 25 parts of medium-chain triglyceride microcapsule powder, 22 parts of towel gourd powder, 15 parts of mucinous-Akkermansia (Akkermansia muciniphila) and 25 parts of fructo-oligosaccharide.
Comparative example 2
A fat-reducing composition comprises the following components in parts by weight: 25 parts of black fruit and rib flower fructus fagopyri powder, 6 parts of medium-chain triglyceride microcapsule powder, 7 parts of towel gourd powder, 2 parts of mucinous-Akkermansia (Akkermansia muciniphila) and 7 parts of fructo-oligosaccharide.
Comparative example 3
A fat-reducing composition comprises the following raw materials in parts by weight: 36 parts of black fruit gland rib flower fructus Sorbi Pohuashanensis juice powder, 15 parts of medium chain triglyceride microcapsule powder, 10 parts of mucinous-Akkermansia (Akkermansia muciniphila) and 16 parts of fructo-oligosaccharide.
Comparative example 4
A fat-reducing composition comprises the following raw materials in parts by weight: 15 parts of medium-chain triglyceride microcapsule powder, 15 parts of towel gourd powder, 10 parts of mucinous-Ackermanella (Akkermansia muciniphila) and 16 parts of fructo-oligosaccharide.
Comparative example 5
A fat-reducing composition comprises the following raw materials in parts by weight: 36 parts of juice powder of fructus nigrum and ribwhat, 15 parts of towel gourd powder, 10 parts of mucinous-Ackermanella (Akkermansia muciniphila) and 16 parts of fructo-oligosaccharide.
Comparative example 6
A fat-reducing composition comprises the following raw materials in parts by weight: 36 parts of black fruit and rib flower fructus Sorbi Pohuashanensis juice powder, 15 parts of medium-chain triglyceride microcapsule powder, 15 parts of towel gourd powder and 16 parts of fructo-oligosaccharide.
Experimental example 1
The weight loss efficacy of the composition of the invention was operated in a rat obesity prevention model method according to the test and evaluation of health food technical criteria (2003 edition) chapter twelfth test method for weight loss function.
Evaluation was carried out.
Test subjects: in the rat test, SPF male Wistar rats with the weight of 160-180 g are selected.
Feed:
basic feed
High-fat feed: 80% of basal feed, 10% of lard oil and 10% of egg yolk powder.
The test method comprises the following steps: all experimental rats (120) were fed basal diet 7d under a barrier system to acclimatize the rats. After the adaptation period is finished, randomly dividing the body weight into a blank group (10) and a test group (110), wherein the blank group is given with basal feed, and the test group is given with high-fat feed; after feeding for 14 days, the rats in the test group are sorted according to the weight gain, and 40 obese resistant rats after the weight gain are eliminated; dividing 6 groups of the rest obesity-sensitive rats randomly according to the body weight to serve as test groups, wherein the test groups are respectively a model group and test groups 1-5, the test groups continue to be fed with high-fat feed, the blank group is fed with basic feed, the test groups 1-3 are fed with the mixture ratio of the compositions of examples 1-3, the test groups 4-5 are respectively fed with the mixture ratio of the compositions of comparative examples 1-2, the recommended amount of a human body is 2.55g/60kg.bw (the main drug amount only), the medium dose group is 425mg/kg.bw (which is 10 times of the recommended intake amount of the human body), purified water is used as a solvent to be matched to the required concentration, each rat is filled with the purified water in a stomach manner according to 0.2mL/10g.bw, and the blank group and the model group are filled with the purified water for 42 days. During this period, the amount of food given, the amount of food scattered and the amount of food left were recorded daily, and the body weight was weighed 1 time every 3 days.
Measurement of rat weight loss index: before the test, the rats are fasted for no water prohibition, after anesthesia, the weights of the rats are weighed, the fat around the kidney and the fat around the testis are dissected and weighed, and the daily food intake of each rat is calculated.
SPSS statistical software is used for data processing, and significance difference analysis is carried out among groups by t test, wherein the difference is significant when P is less than 0.05, and the difference is very significant when P is less than 0.01. The data of all detection indexes are expressed by mean ± standard deviation, and the test results are shown in table 1.
Table 1: influence of experimental group 1-6, model group and control group on weight, in-vivo fat weight and food intake of obese rats
Note:#it is shown that compared to the blank control group,#p is less than 0.05; p < 0.05 compared to model control.
As can be seen from Table 1, the body weight and the body fat weight in the model control group are significantly different from those in the blank control group (P is less than 0.05), and the food intake is not significantly different, which indicates that the modeling is successful; the differences of the weights of the experimental groups 1-3 and the weight of the in vivo fat and the model control group are obvious (P is less than 0.05), the differences of the weights of the experimental groups 4-5 and the weight of the in vivo fat and the model control group are not obvious, and the differences of the food intake of the experimental groups 1-5 and the model control group are not obvious; the results show that the dosage of the composition in the experimental groups 1-3 has a very obvious effect on fat reduction.
Experimental example 2
According to the experimental result of the experimental example 1, the composition ratio in the experimental example 1 is selected, the recommended amount of a human body is 2.55g/60kg.bw (only the main drug amount), the experiment is provided with three low, medium and high dose groups which are respectively 212.5mg/kg.bw, 425mg/kg.bw and 1275mg/kg.bw, the doses of the low, medium and high groups are respectively equal to 5 times, 10 times and 30 times of the recommended intake amount of the human body, the rat experiment is still used for evaluation, and the comparative examples 3-6 are filled according to the high dose groups. The experimental method is the same as that in experimental example 1, 8 groups of rats in the experimental group are divided into a model group and experimental groups 1-7 according to weight, the experimental groups 1-3 are respectively prepared by using three doses of low dose and high dose in example 1, the experimental groups 4-7 are prepared by using the composition in comparative examples 3-6 and using purified water as a solvent to prepare the required concentration, each rat is filled with the purified water by the gavage method of 0.2mL/10g.bw, and the blank group and the model group are filled with the purified water by the gavage method. The rat weight loss index was determined and the data was processed as in example 1, and the experimental indices for each group are shown in table 2:
table 2: influence of experimental group 1-9, model group and control group on weight, in-vivo fat weight and food intake of obese rats
Note:#it is shown that compared to the blank control group,#p is less than 0.05; p < 0.05, P < 0.01, compared to model controls.
As can be seen from the experimental results in Table 2, the body weight and the body fat weight in the model control group are significantly different from those in the blank control group (P is less than 0.05), and the food intake is not significantly different, which indicates that the modeling is successful; the weight and the in vivo fat weight in the experimental group 2-3 are respectively obviously different (P is less than 0.05) and extremely obviously different (P is less than 0.01) from the model control group, but the food intake is not obviously lower than that of the model control group; all indexes (weight of rats, weight of fat in bodies and food intake) in the experimental groups 4-7 are more than 0.05 of the model control group P, and no significant difference exists; the results show that the fruit juice powder of the black fruit and rib flower, the medium chain triglyceride microcapsule powder, the towel gourd powder, the mucinous-Akkermansia (Akkermansia muciniphila) and the fructo-oligosaccharide are cooperated to double the fat, reduce the fat accumulation in the body and regulate the intestinal flora, thereby achieving the fat reducing effect.
Experimental example 3
Regulating intestinal flora
Collection of rat feces
At the end of the rat feeding cycle in experimental example 1, bedding material was removed from each rat cage, and fresh feces collected from each rat cage were placed in different centrifuge tubes. Collecting Song dynasty, rapidly placing in-80 deg.C ultra-low temperature refrigerator for DNA extraction and intestinal flora detection.
IIIuma Miseq PE250 sequencing
The DNA of rat feces of each group was extracted according to the procedures described in the specification of the DNA extraction kit, and the extracted genomic DNA was detected by 1% agarose gel electrophoresis. The extracted DNA sample is stored at-20 ℃.
16SrDNA was performed on the above samples using the IIIuma Miseq PE250 high throughput sequencing protocol, and bioinformatics analysis was performed on the sequencing data, the results are shown in FIG. 1.
The intestinal flora mainly comprises 9 flora, wherein 98% of bacteria can be classified into the following 4, Bacteroides, firmicutes, Proteobacteria and Actinomycetes. The research shows that the relative abundance ratio (F/B ratio) of firmicutes to bacteroidetes in intestinal tracts of obese patients and obese mice is remarkably increased relative to that of thin patients, and then the F/B ratio is reduced again after the obese mice become thin.
Through the analysis of the relative abundance of different phyla of the intestinal flora of the control group of each experimental group, it is obvious that the phyla firmicutes and bacteroidetes occupy absolute advantages in all samples. Compared with a blank control group, the F/B ratio of the model control group is increased and has obvious difference with the blank control group. The F/B ratio in the experimental groups 1-3 is obviously reduced compared with that in the model control group, and has obvious difference (P is less than 0.05), and the F/B ratio in the experimental groups 4-5 has no obvious difference with that in the model control group, which shows that the composition proportion in the experimental groups 1-3 can play a role in regulating the intestinal flora structure of rats.
The above description is only an example of the present application and is not intended to limit the present application. Various modifications and changes may occur to those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the scope of the claims of the present application.
Claims (7)
1. A fat-reducing composition comprises the following raw materials in parts by weight: 30-40 parts of black fruit and rib flower fructus fagopyri juice powder, 10-20 parts of medium-chain triglyceride microcapsule powder, 10-20 parts of towel gourd powder, 3-13 parts of mucinous-akkermansia (Akkermansia muciniphila) and 10-20 parts of fructo-oligosaccharide.
2. The fat-reducing composition according to claim 1, comprising the following raw materials in parts by weight: 33-37 parts of juice powder of fructus akebiae, 13-17 parts of medium-chain triglyceride microcapsule powder, 12-18 parts of towel gourd powder, 5-12 parts of mucinous-Akkermansia (Akkermansia muciniphila) and 12-17 parts of fructo-oligosaccharide.
3. The fat-reducing composition according to claim 1, comprising the following raw materials in parts by weight: 36 parts of black fruit gland and rib flower fructus fagopyri powder, 15 parts of medium chain triglyceride microcapsule powder, 15 parts of towel gourd powder, 10 parts of mucinous-Akkermansia (Akkermansia muciniphila) and 16 parts of fructo-oligosaccharide.
4. The fat-reducing composition according to claim 1, wherein the medium-chain triglyceride microcapsule powder contains 70 to 80% by weight of medium-chain triglyceride.
5. A process for preparing a fat reducing composition as claimed in claim 1 comprising the steps of:
(1) sieving fructus Sorbi Pohuashanensis juice powder, medium chain triglyceride microcapsule powder, fructus Luffae powder, and fructo-oligosaccharide with 80 mesh sieve, mixing at a certain proportion to obtain mixture, and adding alcohol into the mixture to obtain soft material; then, granulating through a 20-mesh sieve, drying for 2-3 h at 50-60 ℃ after granulation, and then carrying out granulation and powder sieving to obtain a primary mixture;
(2) and (2) adding the mucinous-Ackermanella (Akkermansia) into the primary mixture obtained in the step (1) according to the proportion, and mixing for 20-25 min to obtain the fat-reducing composition.
6. The method according to claim 5, wherein in the step (1), the alcohol is added in an amount of 5 to 10% by weight based on the weight of the mixture, at a concentration of 40 to 60% by weight.
7. An oral preparation for reducing fat, which is prepared from the fat-reducing composition of claim 1, and is in the form of tablets, capsules or granules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010807727.6A CN111713666B (en) | 2020-08-12 | 2020-08-12 | Fat reducing composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010807727.6A CN111713666B (en) | 2020-08-12 | 2020-08-12 | Fat reducing composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111713666A true CN111713666A (en) | 2020-09-29 |
| CN111713666B CN111713666B (en) | 2023-04-07 |
Family
ID=72574257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010807727.6A Active CN111713666B (en) | 2020-08-12 | 2020-08-12 | Fat reducing composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111713666B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113750172A (en) * | 2021-09-01 | 2021-12-07 | 西安诺众康健生物科技有限责任公司 | A kind of weight loss composition and its application in the preparation of weight loss products |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2919796A1 (en) * | 2012-11-19 | 2015-09-23 | Université catholique de Louvain | Use of akkermansia for treating metabolic disorders |
| CN111227233A (en) * | 2020-03-02 | 2020-06-05 | 中国农业大学 | Application of loofah powder in improving hyperbranched chain amino acid hyperemia and inhibiting obesity |
| CN111374308A (en) * | 2020-04-10 | 2020-07-07 | 天津国民健康技术有限公司 | Composition for controlling sugar, reducing fat and losing weight and preparation method thereof |
-
2020
- 2020-08-12 CN CN202010807727.6A patent/CN111713666B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2919796A1 (en) * | 2012-11-19 | 2015-09-23 | Université catholique de Louvain | Use of akkermansia for treating metabolic disorders |
| CN111227233A (en) * | 2020-03-02 | 2020-06-05 | 中国农业大学 | Application of loofah powder in improving hyperbranched chain amino acid hyperemia and inhibiting obesity |
| CN111374308A (en) * | 2020-04-10 | 2020-07-07 | 天津国民健康技术有限公司 | Composition for controlling sugar, reducing fat and losing weight and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 刘竺云，等: "《非无菌制剂技术》", vol. 1, 30 September 2018, 江苏大学出版社, pages: 149 * |
| 孙智谋，等: "黑果腺肋花楸花青素抗氧化功能的研究进展", 《食品研究与开发》, vol. 38, no. 16, 31 August 2017 (2017-08-31), pages 220 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113750172A (en) * | 2021-09-01 | 2021-12-07 | 西安诺众康健生物科技有限责任公司 | A kind of weight loss composition and its application in the preparation of weight loss products |
| CN113750172B (en) * | 2021-09-01 | 2022-06-28 | 西安诺众康健生物科技有限责任公司 | A kind of weight loss composition and its application in the preparation of weight loss products |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111713666B (en) | 2023-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101965969B (en) | Health-care food composition with anti-fatigue and immunity-improving functions and preparation method and application thereof | |
| TWI627959B (en) | Use of lactobacillus reuteri gmnl-263 for manufacturing composition for increasing expression of ldl-r and cyp7a1 in liver in high-fat diet individual | |
| CN111164201B (en) | Lactobacillus paracasei GKS6 for improving metabolic syndrome, its uses, pharmaceutical compositions and edible compositions | |
| TWI830696B (en) | Compositions for inhibiting muscle fiber degeneration | |
| CN110612111A (en) | Composition for preventing, improving or treating visceral fat type obesity containing salvia miltiorrhiza extract | |
| TW201917205A (en) | A Lactobacillus plantarum, composition, culturing method and use of elimination of body fat, reduction of hepatomegaly and/or anti-inflammatory | |
| He et al. | Laxative effect of mulberry ferment on two models of constipated mice | |
| CN106962933B (en) | Application of nymphaea hybrid extract and composition thereof in preventing obesity and improving intestinal flora | |
| CN115316497A (en) | Mulberry leaf extract, mandarin fish feed and application thereof | |
| Jia et al. | The potential mechanisms of Macrocystis pyrifera polysaccharides mitigating type 2 diabetes in rats | |
| CN108904763A (en) | Composition and its preparation method and application containing compound lactobacillus | |
| CN111713666B (en) | Fat reducing composition and preparation method thereof | |
| Shen et al. | Effect of Echinacea purpurea extract given in drinking water on performance, slaughter variables, and meat quality of broilers | |
| CN108741085A (en) | Application of the pectin in preparing the functional food with fat-reducing effect | |
| CN101912407B (en) | Composition for weight loss and fat reduction | |
| Long et al. | Maternal dietary Forsythia suspensa extract supplementation induces changes in offspring antioxidant status, inflammatory responses, intestinal development, and microbial community of sows | |
| KR101709246B1 (en) | Anti-obesity synbiotics composition with Laminaria and lactic acid bacteria complex | |
| CN116178579B (en) | A kind of black skin Alpinia thunbergii polysaccharide and its preparation method and application | |
| CN102783568A (en) | Feed additive | |
| CN110123824B (en) | Ilicis Pubescentis saponin A1New use of | |
| Wang et al. | Effects of polysaccharide fermentation with Bacillus coagulans on growth, antioxidant and immunity of Macrobrachium nipponense (riental river prawn) | |
| CN114177208A (en) | Application of custard apple seed ethanol extract in preparation of lipid-lowering and weight-losing medicine | |
| JP2004091433A (en) | Composition for improving inflammatory disease | |
| CN115777817B (en) | Plant extract composition for dispelling effects of alcohol, protecting liver, moistening intestines and relaxing bowels, health tea and preparation method | |
| CN111329928B (en) | Composition containing camellia oil and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |